Cargando…
Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
Palliative radiotherapy is currently the medical standard of care for non-small-cell lung cancer (NSCLC) patients with symptomatic CNS and leptomeningeal disease. We report the case of a 62-year-old male patient with EGFR mutation (del19+) NSLC with symptomatic lymph node, bone, CNS, and leptomening...
Autores principales: | Llinás-Quintero, Néstor, González-Hoyos, David, Yepes, Andrés, Herrera, Diego A., Peláez-Arroyave, Sebastián, Caicedo-Zamudio, Carlos, Blanco-Daza, Erick, Cuello-López, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766146/ https://www.ncbi.nlm.nih.gov/pubmed/31637072 http://dx.doi.org/10.1155/2019/1939703 |
Ejemplares similares
-
Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020) -
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018) -
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022) -
Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023) -
Absence of copy number gain of EGFR: A possible predictive marker of long‐term response to afatinib
por: Nakamura, Tomomi, et al.
Publicado: (2022)